For secondary endpoints, proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK) plus statin (PCSK/ST) significantly reduced the risk of non-fatal MI (RR 0.82, 95% CI 0.72-0.93, <i>p</i> = 0.003), stroke (RR 0.74, 95% CI 0.65-0.85, <i>p</i> < 0.001), coronary revascularization (RR 0.84, 95% CI 0.75-0.94, <i>p</i> = 0.003) compared to ST. Here, PCSK9 is linked to Stroke.